Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Market price (% of par)
-
122.69%
-
Total 13F principal
-
$213,294,000
-
Principal change
-
+$650,000
-
Total reported market value
-
$262,094,000
-
Number of holders
-
17
-
Value change
-
-$665,818
-
Number of buys
-
4
-
Number of sells
-
9
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q3 2017
As of 30 Sep 2017 THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 had 17 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $213,294,000 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Linden Advisors LP, CITADEL ADVISORS LLC, BAUPOST GROUP LLC/MA, WOLVERINE ASSET MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, ZAZOVE ASSOCIATES LLC, Verition Fund Management LLC, FMR LLC, GEODE CAPITAL MANAGEMENT, LLC, and Context Capital Management, LLC.
This table shows 17 bond principal holders of the security as of 30 Sep 2017.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par) |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.